Immunotherapy for tuberculosis: current strategies and future directions.

Area of Science:

• Immunology
• Infectious Diseases
• Drug Discovery

Background:

• Drug-resistant tuberculosis (TB) poses a significant global health challenge, hindering conventional antimicrobial treatments.
• Mycobacterium tuberculosis (M. tuberculosis) infection leads to host cell exhaustion, suppressing immune responses and initiating TB.
• Understanding TB immunopathogenesis reveals the potential of host-directed immunotherapeutic strategies.

Purpose of the Study:

• To comprehensively review advancements in diverse TB immunotherapeutic strategies.
• To explore the efficacy, safety, and administration methods of current TB immunotherapies.
• To discuss the challenges and future prospects of immunotherapy for TB management.

Main Methods:

• Review of current scientific literature on TB immunopathogenesis and immunotherapy.
• Analysis of immunotherapeutic approaches including cell therapy and immune checkpoint inhibitors.
• Evaluation of mechanisms targeting host immune responses against M. tuberculosis.

Main Results:

• Immunotherapies aim to restore host immune homeostasis and anti-TB activities like cytokine production and autophagy.
• Approaches like cell therapy and immune checkpoint inhibitors show promise in restoring immunity and therapeutic effects.
• Restoring the balance between T helper 1 (Th1) and T helper 2 (Th2) responses is a key aspect of these strategies.

Conclusions:

• Immunotherapy holds significant potential to revolutionize TB management and improve patient outcomes.
• Further comprehensive evaluation of safety, treatment duration, and other factors is crucial for clinical integration.
• Continued research and development in TB immunotherapy are essential to overcome challenges and realize its full potential.